Does Adjuvant Immune Checkpoint Inhibition Therapy Have a Future in Operable Bladder Cancer?
No Thumbnail Available
Authors
Coca Membribes,Sara
Powles,Thomas
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
Use of adjuvant immune checkpoint inhibitors (ICIs) in muscle-invasive bladder cancer is likely to continue, but predominantly in patients who have already started an ICI as part of a perioperative regimen rather than as a stand-alone strategy after radical cystectomy (RC) for high-risk cases. Further trials are required to define the optimal adjuvant ICI duration in this setting. As systemic therapy is increasingly prioritised over RC, truly adjuvant ICI use after RC in ICI-naïve patients is expected to become much less frequent than it is today.
Description
Citation
Publisher
License
Journal
European urology focus